303 related articles for article (PubMed ID: 23307208)
41. Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience.
Habot-Wilner Z; Frenkel S; Pe'er J
Br J Haematol; 2021 Jul; 194(1):92-100. PubMed ID: 33900619
[TBL] [Abstract][Full Text] [Related]
42. Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes.
Hoffman PM; McKelvie P; Hall AJ; Stawell RJ; Santamaria JD
Eye (Lond); 2003 May; 17(4):513-21. PubMed ID: 12802353
[TBL] [Abstract][Full Text] [Related]
43. Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma.
Cheng CL; Yeh PT; Fang WQ; Ma WL; Hou HA; Tsai CH; Lin CP; Tien HF
Cancer Med; 2023 Apr; 12(7):8102-8111. PubMed ID: 36602288
[TBL] [Abstract][Full Text] [Related]
44. Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes.
Abu Samra K; Oray M; Ebrahimiadib N; Lee S; Anesi S; Foster CS
Ocul Immunol Inflamm; 2018; 26(3):347-352. PubMed ID: 27438792
[TBL] [Abstract][Full Text] [Related]
45. Incidence, clinical features, treatment and outcome of primary central nervous system lymphoma in Norway.
Salvesen Haldorsen I; Aarseth JH; Hollender A; Larsen JL; Espeland A; Mella O
Acta Oncol; 2004; 43(6):520-9. PubMed ID: 15370608
[TBL] [Abstract][Full Text] [Related]
46. Analysis of clonal immunoglobulin heavy chain rearrangements in ocular lymphoma.
Baehring JM; Androudi S; Longtine JJ; Betensky RA; Sklar J; Foster CS; Hochberg FH
Cancer; 2005 Aug; 104(3):591-7. PubMed ID: 15973665
[TBL] [Abstract][Full Text] [Related]
47. Ophthalmic lymphoma: epidemiology and pathogenesis.
Sjö LD
Acta Ophthalmol; 2009 Feb; 87 Thesis 1():1-20. PubMed ID: 19178392
[TBL] [Abstract][Full Text] [Related]
48. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.
Grimm SA; McCannel CA; Omuro AM; Ferreri AJ; Blay JY; Neuwelt EA; Siegal T; Batchelor T; Jahnke K; Shenkier TN; Hall AJ; Graus F; Herrlinger U; Schiff D; Raizer J; Rubenstein J; Laperriere N; Thiel E; Doolittle N; Iwamoto FM; Abrey LE
Neurology; 2008 Oct; 71(17):1355-60. PubMed ID: 18936428
[TBL] [Abstract][Full Text] [Related]
49. [Vitrectomy in oculocerebral non-Hodgkin's lymphoma].
Messerli J; Kraft R; Körner F
Ophthalmologe; 1993 Oct; 90(5):448-51. PubMed ID: 8219629
[TBL] [Abstract][Full Text] [Related]
50. Vitreoretinal lymphoma: Central nervous system lymphoma risk with unilateral or bilateral ocular tumour. A multicentre collaboration.
Dalvin LA; Pulido JS; Shields CL; Marchese A; Miserocchi E; Frenkel S; Pe'er J
Eye (Lond); 2023 Jan; 37(1):54-61. PubMed ID: 34999721
[TBL] [Abstract][Full Text] [Related]
51. Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.
Kaburaki T; Taoka K
Jpn J Ophthalmol; 2023 Jul; 67(4):363-381. PubMed ID: 37209195
[TBL] [Abstract][Full Text] [Related]
52. Primary CNS lymphoma in immunocompetent patients from 1989 to 2001: a retrospective analysis of 164 cases uniformly diagnosed by stereotactic biopsy.
Feuerhake F; Baumer C; Cyron D; Illerhaus G; Olschewski M; Tilgner J; Ostertag CB; Volk B
Acta Neurochir (Wien); 2006 Aug; 148(8):831-8; discussion 838. PubMed ID: 16791439
[TBL] [Abstract][Full Text] [Related]
53. The importance of cytokines analysis in the diagnosis of vitreoretinal lymphoma.
Frenkel S; Pe'er J; Kaufman R; Maly B; Habot-Wilner Z
Acta Ophthalmol; 2020 Sep; 98(6):e668-e673. PubMed ID: 31994839
[TBL] [Abstract][Full Text] [Related]
54. Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A Potential Less Invasive Method for Diagnosis and Treatment Response Assessment.
Demirci H; Rao RC; Elner VM; Demirci FY; Axenov L; Betz B; Behdad A; Brown N
Ophthalmol Retina; 2023 Feb; 7(2):189-195. PubMed ID: 35952929
[TBL] [Abstract][Full Text] [Related]
55. Vitreoretinal Lymphoma: Optimizing Diagnostic Yield and Accuracy.
Santos MC; Jiang A; Li AS; Rao PK; Wilson B; Harocopos GJ
Am J Ophthalmol; 2022 Apr; 236():120-129. PubMed ID: 34626574
[TBL] [Abstract][Full Text] [Related]
56. Aurora borealis and string of pearls in vitreoretinal lymphoma: patterns of vitreous haze.
Marchese A; Miserocchi E; Giuffrè C; Cicinelli MV; Querques G; Bandello F; Modorati G
Br J Ophthalmol; 2019 Nov; 103(11):1656-1659. PubMed ID: 30709808
[TBL] [Abstract][Full Text] [Related]
57. Cytopathological analysis of vitreous in intraocular lymphoma.
Intzedy L; Teoh SC; Hogan A; Mangwana S; Mayer EJ; Dick AD; Pawade J
Eye (Lond); 2008 Feb; 22(2):289-93. PubMed ID: 17767143
[TBL] [Abstract][Full Text] [Related]
58. Clinical Characteristics of Primary Vitreoretinal Lymphoma in an Indian Population.
Mahajan S; Nijhawan R; Rajwanshi A; Karkhur S; Mulkutar S; Dogra M; Lal V; Gupta V; Gupta A
Ocul Immunol Inflamm; 2017 Oct; 25(5):633-638. PubMed ID: 27003620
[TBL] [Abstract][Full Text] [Related]
59. Concurrent primary vitreoretinal and spinal cord lymphoma: a unique entity.
Ezon IC; Barteselli G; Rosenberg J; Freeman WR
JAMA Ophthalmol; 2014 Jul; 132(7):902-4. PubMed ID: 25010176
[No Abstract] [Full Text] [Related]
60. Primary intraocular lymphoma: clinical, cytologic, and flow cytometric analysis.
Zaldivar RA; Martin DF; Holden JT; Grossniklaus HE
Ophthalmology; 2004 Sep; 111(9):1762-7. PubMed ID: 15350334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
